Global Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians - Scorecard - MDSpire
Advertisement
Global Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians
Clinical Scorecard: International Variability in Clinical Approaches to Clostridioides difficile Infections: A Cross-Sectional Survey of Healthcare Professionals
At a Glance
Category
Detail
Condition
Clostridioides difficile infections (CDIs)
Key Mechanisms
Nosocomial infection with significant morbidity, mortality, and economic burden; recurrence common; diagnosis and treatment vary internationally
Target Population
Adult patients with CDI managed by attending physicians, infectious disease pharmacists, and infectious diseases or medical microbiology fellows
Care Setting
Hospital and clinical settings globally, across multiple continents
Key Highlights
Significant global variability exists in CDI diagnosis, treatment, and secondary prophylaxis practices.
A 2-step diagnostic algorithm is used by 75.8% of clinicians, but assay types vary widely.
Oral vancomycin is the most common agent for secondary prophylaxis, with wide variation in dosing and duration.
Guideline-Based Recommendations
Diagnosis
Use of a 2-step CDI diagnostic algorithm is common but assay types differ internationally.
Diagnostic testing recommendations vary among ACG, AMMI Canada, ESCMID, and IDSA guidelines.
Management
First-line treatment agents for initial and recurrent uncomplicated CDI episodes vary significantly.
No consensus exists on treatment approaches for fulminant CDI.
Secondary CDI prophylaxis during antibiotic re-exposure is practiced variably, most commonly in North America.
Monitoring & Follow-up
No specific monitoring protocols detailed; variability in clinical practice suggests need for standardized approaches.
Risks
High recurrence rate (~30%) and mortality (~5%) associated with CDI.
Economic burden significant, exceeding $6 billion annually in the US.
Patient & Prescribing Data
Adults with CDI managed by experienced clinicians across 31 countries and 6 continents.
Oral vancomycin is predominantly used for secondary prophylaxis (96.3%), with doses ranging from 125 to 500 mg daily and durations from 1 to 28 days.
Clinical Best Practices
Employ a 2-step diagnostic algorithm for CDI to improve diagnostic accuracy.
Consider oral vancomycin for secondary prophylaxis during antibiotic re-exposure, tailoring dose and duration to patient needs.
Recognize the lack of international consensus and adapt management based on local guidelines and clinical judgment.
Identify knowledge gaps and support enrollment in randomized controlled trials to establish harmonized CDI management.
